Hypertrophic cardiomyopathy (HCM) is triggered mainly by mutations in genes encoding sarcomeric proteins, but a significant proportion of patients lack a genetic diagnosis. We identified a novel mutation in the ryanodine receptor 2, RyR2-P1124L, in a patient from a genotype-negative HCM cohort. The aim of this study was to determine whether RyR2-P1124L triggers functional and structural alterations in isolated RyR2 channels and whole hearts. We found that P1124L induces significant conformational changes in the SPRY2 domain of RyR2. Recombinant RyR2-P1124L channels displayed a cytosolic loss-offunction phenotype, which contrasted with a higher sensitivity to luminal [Ca 2+ ], indicating a luminal gain-of-function. Homozygous mice for RyR2-P1124L showed mild cardiac hypertrophy, similar to the human patient. This phenotype, evident at 1 yr of age, was accompanied by an increase in the expression of calmodulin (CaM). P1124L mice also showed higher susceptibility to arrhythmia at 8 mo of age, before the onset of hypertrophy. RyR2-P1124L has a distinct cytosolic loss-of-function and a luminal gain-of-function phenotype. This bifunctionally-divergent behavior triggers arrhythmias and structural cardiac remodeling, and involves overexpression of calmodulin as a potential hypertrophic mediator. This study is relevant to continue elucidating the possible causes of genotypenegative HCM and the role of RyR2 in cardiac hypertrophy.
Introduction
Hypertrophic cardiomyopathy (HCM) is one of the most common congenital cardiac diseases, affecting approximately one out of every 500 individuals (0.2% of the general population) (1) . HCM is characterized at the tissue level by myocyte hypertrophy and disarray, and interstitial fibrosis. Clinical features involve thickening of the left ventricle (LV) wall, diastolic dysfunction, heart failure, and increased risk of life-threatening arrhythmias that may lead to sudden cardiac death (SCD) (2, 3) . Mutations affecting over 24 genes have been implicated in the pathogenesis of HCM (4, 5) , most commonly encoding sarcomeric proteins. For example, mutations in the genes MYH7 and MYPBC3, encoding myosin heavy chain 7 and cardiac myosinbinding protein C (MyBP-C), respectively, account for approximately 90% of patients with HCM who have a positive genetic test result (6) . However, approximately half of the patients who meet the diagnostic criteria of HCM and undergo genetic testing are negative for mutations in the genes included in HCM panels (4, 7) . As genetic testing has become more common and gene panels expand, new HCM-associated mutations have been identified in several genes encoding the myofilaments and beyond. While rare, there are reports suggesting that mutations in genes encoding Ca 2+ -handling proteins contribute to HCM pathogenesis, including genes such as SRI (sorcin), CASQ2 (calsequestrin 2), TNNC1 (troponin C1), and RYR2 (ryanodine receptor 2, RyR2) (8) . Except for a limited number of TNNC1 mutations (9) , HCM associated to perturbations in Ca 2+ -handling proteins has not been characterized thoroughly.
RyR2 is the major Ca 2+ release channel in the heart and localizes on the sarcoplasmic reticulum (SR). During an action potential, a small inward Ca 2+ current through L-type Ca 2+ channels activates RyR2, triggering more Ca 2+ release from the SR. RyR2 provides most of the Ca 2+ required for this process, called excitation-contraction (e-c) coupling. Tight regulation of Ca 2+ release in the heart, and thus of RyR2 function, is essential because the same Ca 2+ used for e-c coupling can induce Ca 2+ -dependent arrhythmias (10) or modulate hypertrophic signaling pathways (11) . Over the last 20 years, nearly 200 RyR2 mutations have been identified in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) (12) , a disorder involving severe ventricular arrhythmias triggered by stress, but without structural alterations of the myocardium. The mechanisms underlying RyR2-mediated CPVT (CPVT1) have been the subject of extensive research, uncovering a variety of molecular and cellular mechanisms for Ca 2+ mishandling and, ultimately, arrhythmia. More recently, a RyR2 mutation, T1107M, was reported in a family with HCM (13) . This mutation generated considerable interest in the field, as it was the first RyR2 variant potentially contributing to a structural disorder (HCM) rather than an entirely functional disorder (CPVT). Recombinant A1107M, the mouse analog, behaved considerably different in a heterologous expression system when compared to other CPVT1 mutations, suggesting a different pathogenic mechanism (14) . T1107M has also appeared in cohorts of whole-exome sequencing (WES) (15) and of CPVT patients (16) , weakening its potential as an HCM-associated mutation. Altogether, these data indicated that RyR2 can produce a wide range of cardiac dysfunctions, but the link between RyR2 mutations and structural cardiomyopathy remains elusive.
In this study, we describe the comprehensive characterization of a novel RyR2 variant (P1124L), identified in a patient with sarcomere mutation-negative HCM. While the P1124L variant is in the same domain as T1107M, herein we present defining characteristics of P1124L that bolster its potential association with the patient's phenotype, including a) satisfying a genetic criterion (identification of a rare variant in RYR2 in a patient with HCM), b) in silico tools suggesting pathogenicity, c) molecular and functional criteria (validation assays demonstrating that this variant is disruptive functionally), and d) whole organism/animal model criterion (mice harboring P1124L develop arrhythmia and hypertrophy, although not as dramatically as the patient). Hearts from P1124L mice showed an increase in the expression of calmodulin (CaM), a classical inhibitor of RyR2 and signaling molecule, but had no significant changes in the expression of downstream signaling molecules involved in hypertrophy. Thus, although the precise molecular mechanism(s) underlying hypertrophy in P1124L mice could not be fully discerned and need further study, here we offer evidence that links RyR2 dysfunction with cardiac hypertrophic remodeling, in addition to the demonstrated role of this protein in the pathogenicity in CPVT.
Results

Identification of RyR2-P1124L in a Human Patient with HCM
Among the 36 patients with genotype negative/phenotype positive HCM who underwent WES, in one of them we identified a novel, candidate HCM-associated variant in RYR2, P1124L, without any other candidate disease-associated mutations. This RyR2-P1124L-positive patient was a male diagnosed with HCM at 17 years of age following a syncopal episode and was placed on β-blocker therapy. Four months later, because of persistent chest tightness and paroxysmal nocturnal dyspnea, he received a dual chamber pacemaker elsewhere. He was evaluated at Mayo Clinic 1 yr later, exhibiting moderate concentric hypertrophy (21 mm) in the absence of hypertension ( Figure S1 ). The ejection fraction (EF) was 75% with decreased left ventricle (LV) chamber size and hyperdynamic function. Obstruction of the left ventricle outflow tract (LVOT) was dynamic measuring 46 mmHg at rest, increasing to 88 mmHg after provocation. There was also evidence of systolic anterior motion of the mitral valve with grade III/IV mitral regurgitation.
ECG monitoring showed artifacts consistent with a rhythm maintained by firing of the pacemaker, but without signs of ventricular arrhythmia. Because the symptoms remained refractory to pharmacotherapy and pacing, the patient underwent an extensive surgical myectomy at Mayo
Clinic. An ECG performed four days post-surgery showed normal sinus rhythm, signs of left atrial enlargement, left ventricular hypertrophy and QRS widening. (17) .
To determine the potential association between P1124L and HCM, we studied this mutation on multiple levels.
Localization of P1124L in the Three-Dimensional Structure of RyR2
CPVT1-associated RyR2 mutations mainly cluster in four "hot spots", which coincide with functional domains of the channel, called CPVT-I to IV ( Figure 1A ). P1124, a highly conserved residue among species ( Figure 1B ) and RyR isoforms ( Figure S2 ), is located outside these hot spots in SPRY2, one of the three SPRY domains of RyR2 ( Figure 1C ) . The crystal structures of SPRY1 and SPRY2 were solved recently to a resolution below 1.5 Å (18, 19) , while highresolution structures of SPRY3 are not available. P1124 is part of a flexible linker connecting strands β2 and β3 that was not included in the initial SPRY2 model due to poor electron density;
yet, recent cryo-EM structures of RyR1 and RyR2 suggest that this loop is at the SPRY2-SPRY3 interface ( Figure 1D ) (20, 21) .
Since all RyR cryo-electron microscopy (cryo-EM) structures originate from native material, analyzing RyR disease mutants is currently not feasible. We therefore crystallized the SPRY2 domain containing the P1124L mutation and solved its structure at an average 1.44 Å resolution. The loop containing the mutation is well-ordered, in contrast to the WT, which shows less defined density (19) . The WT loop could still be traced, and thus we further refined this structure to allow a direct comparison ( Figure S3 and Figure S4 , Table S1 ). Introducing the proline to leucine substitution produces an extensive conformational change that affects neighboring residues, notably C1122 and D1125, with D1125 swinging outside and facing SPRY3 ( Figure   1E ,F and Figure S4 ). Also, a new salt bridge forms between R1119 and D1132, located in opposite ends of the β2-β3 linker. Overall, these changes provide stability to the β2-β3 linker, explaining why the density for this loop is better defined in the P1124L mutant. Details of the SPRY2-SPRY3 interactions cannot yet be discerned in the cryo-EM reconstructions, because the local resolution in those areas is low. However, just like mutations analyzed in the N-terminal disease hot spot, such changes at interdomain interfaces are likely to cause relative domain orientations that indirectly affect channel gating (22, 23) . For example, the altered D1125 side chain may affect interactions with R1599 in SPRY3, although this remains to be tested.
Molecular Phenotype of P1124L-Containing RyR2 Channels
To determine the possible molecular alterations induced by P1124L in RyR2, we introduced the mutation into the mouse Ryr2 cDNA, and expressed the WT or P1124L protein in HEK293 cells. The approach is justified because P1124 and the neighboring region of SPRY2 are highly conserved among species ( Figure 1B , Figure S2 ). Indeed, within the entire SPRY2 domain, mouse and human RyR2 protein only differ in the three residues highlighted in Figure   1B . 48 hr post-transfection, cell lysates were used for functional studies. We found that expression of P1124L-containing RyR2 channels was significantly reduced compared to the WT RyR2
( Figure S5A ). This is an uncommon observation (reported only for one CPVT-associated mutation (24)), as mutation-harboring RyR2 channels are often expressed to the same level as WT channels in this heterologous system (14) . 
Single Channel Recordings
Recombinant RyR2 channels from heterologous systems are expressed in the absence of other important regulatory co-factors. Therefore, we prepared SR-enriched microsomal fractions from pooled WT or homozygous P1124L mouse hearts to assess RyR2 activity from native channels reconstituted in planar lipid bilayers (the strategy used to create mice harboring P1124L is described in the following sections). Figure 2E ,F show representative current traces and histograms obtained from single RyR2 channels from SR microsomes. P1124L channels showed lower open probability than WT channels ( Figure 2G ) at nominally-free [Ca 2+ ] (3-5 μM), while average unitary current at 0 mV in a Cs + gradient was not altered (trans/cis 300/50 mM; Figure 2H ). These data agree with the [ Figure 3A shows representative FRET traces measured in cells expressing WT and P1124L channels. From these recordings, we determined the FRET level at which Ca 2+ oscillations activate (FAct) and terminate (FTerm). 1 mM tetracaine was perfused to inhibit RyR2 and determine the FRET level at maximum store capacity (FMax), followed by 20 mM caffeine to empty the ER and determine the residual FRET signal (FMin).
The store capacity was determined as FMax -Fmin. In both groups, the activation threshold was ~80% of the maximum ER store capacity ( Figure 3B ); however, P1124L showed a significant reduction in the termination threshold ( Figure 3C ), resulting in a larger fractional release ( Figure   3D ). These observations did not involve a change in the maximum capacity of the ER store ( Figure   3E was not different ( Figure 3F ), cells expressing P1124L channel showed an increased number of oscillations over the monitoring period ( Figure 3G ). Similar to HEK293 cells with transient transfection of P1124L, cells with stable expression also showed lower RyR2 expression ( Figure   S5B ). The lower expression of P1124L channels may suggest reduced stability of the channel protein in heterologous systems, but this remains to be tested. Altogether, these data suggest that P1124L channels have impaired luminal regulation and, upon activation, may release more Ca 2+ than WT channels.
Generation and Cardiac Structural Phenotype of P1124L Knock-In Mice
Knock-in RyR2-P1124L mice were generated following the strategy summarized in Figure   S6A . Using homologous recombination, we introduced three base substitutions in exon 28 of Ryr2 ( Figure S6B ): a silent A to G substitution in codon 1123, creating a PvuII restriction site; and two substitutions in codon 1124, accounting for the proline (P) to leucine (L) change. P1124L mice show Mendelian propagation ( Figure S6C ). To determine the physiological effect of the molecular dysfunction observed in RyR2-P1124L channels, we performed a thorough characterization of the mice harboring the mutation. At 8 mo of age, both homozygous (Homo) and heterozygous (Het) P1124L mice showed comparable cardiac structure and function with WT littermates, although Homo mice also showed significantly lower hear rate (HR) than Het mice (Table S2 ). At 1 yr of age, this difference in HR was no longer evident and RyR2-P1124L mice showed mild but significant hypertrophy ( Figure 4A , Table S3 ). This phenotype is evident in both Homo and Het mice, and involves thickening of the posterior wall ( Figure 4B ) and septum ( Figure 4C ), without deterioration of the ejection fraction ( Figure 4D ). In both Het and Homo mice, we also observed a significant increase in heart weight as percentage of BW ( Figure 4E ), without significant differences in BW (Table S3) . We did not observe microscopic alterations of the cardiac muscle or fibrotic infiltrations (fibrosis quantification; WT: 4.54±0.57%, Het: 5.21±0.74%, Homo:
4.19±0.57%; p > 0.05, t-test. Figure 4A ).
As an independent test of hypertrophy, we measured isolated ventricular myocytes from 1 yr-old P1124L mice. To avoid bias, fields of view were selected randomly to observe myocytes plated on 35 mm glass-bottom dishes. Myocytes within the field of view were centered and focused prior to collecting transmitted-light images using a confocal microscope; measurements were performed offline. All the cells in an image were measured unless they were partially out of frame or out of focus ( Figure 5A ). While we did not detect a difference in cell width ( Figure 5B ), Homo myocytes were longer than WT and Het myocytes ( Figure 5C ), resulting in Homo myocytes having a significantly larger surface area than WT ( Figure 5D ). Finally, we measured the cardiac expression of three hypertrophic gene markers using qPCR: natriuretic peptide A (Nppa), natriuretic peptide B (Nppb), and myosin heavy chain 7 (Myh7). Consistent with the mild hypertrophy, we only measured a significant increase in Nppa expression in Homo mice ( Figure   5E ).
Taken together, these data suggest that P1124L induces mild cardiac hypertrophy without overt hemodynamic dysfunction in mice, similar to the patient's clinical presentation. This structural phenotype is detectable in both Homo and Het mice, but the number of significant differences in indexes of hypertrophy were greater in Homo mice. We have followed P1124L mice for ~70 weeks of age (~1.3 yrs) without observing evident differences in sudden death or overall mortality.
Signaling Pathways Associated with Cardiac Hypertrophy
To determine the mechanisms by which P1124L might induce hypertrophy, we used
Western blots to measure the expression and phosphorylation of relevant signaling molecules.
Unlike our previous observation in HEK293 cells, we did not detect differences in the expression of RyR2 in mice under 8 mo or over 1year of age ( Figure 6B ). This suggests that the mechanisms reducing the expression of P1124L channels in heterologous systems are compensated for in the mouse heart. Additionally, we did not observe differences in the phosphorylation level of RyR2 We also measured the expression of CnA, the catalytic subunit of CaN ( Figure S9D ). Again, there was no significant difference among genotypes. We therefore moved upstream in the signaling cascade and measured the expression of CaM. Remarkably, CaM was increased in hearts from mice over 1 yr of age but not in mice younger than 8 mo ( Figure 6C ). This difference was only significant in Homo mice, consistent with the more prominent phenotype discussed in the previous section. Transgenic overexpression of CaM (27, 28) and increased levels of free CaM dissociated from RyR2 channels (29) have been linked to cardiac hypertrophy due to activation of downstream signaling. Other hypertrophic signaling pathways reported in a mouse model of severe cardiac hypertrophy due to inability of RyR2 to bind CaM (30) were not altered in P1124L mice ( Figure S9C ,D).
Cellular Ca 2+ Handling in Ventricular Myocytes
The cytosolic loss-of-function phenotype displayed by P1124L channels could lead to reduced Ca 2+ release, contractility and compensatory hypertrophy. Hence, we measured the kinetics of Ca 2+ handling in isolated myocytes from 1 yr-old mice to determine whether P1124L induces alterations of intracellular Ca 2+ homeostasis. We first paced the cells at 1 Hz to quantify the properties of the cellular Ca 2+ transient at basal conditions and in the presence of Isoproterenol (Iso). We observed no significant differences in Ca 2+ release, Ca 2+ removal, or SR content between WT and P1124L myocytes ( Figure S10 , Table S4 ). Next, we studied the propensity for spontaneous Ca 2+ release during a 30 s resting period, following a train of 3 Hz stimulation ( Figure   7A ). The propensity for SCR was higher in Homo myocytes at basal conditions, compared to WT and Het ( Figure 7B ). This difference was reduced by Iso; however, the frequency of SCR was still significantly higher in Homo myocytes treated with Iso than in WT ( Figure 7C 
Arrhythmia Susceptibility of P1124L Mice
The high incidence of diastolic Ca 2+ waves in RyR2-P1124L cardiomyocytes suggest that mice harboring the mutation may be more susceptible to develop cardiac arrhythmia. We used a challenge protocol (i.p. injection of epinephrine 2 mg/kg and caffeine 120 mg/kg) (31) during surface ECG recording, to determine the susceptibility of P1124L mice to develop ventricular arrhythmia. We performed this test in 8 mo-old mice because at this age they do not show signs of cardiac hypertrophy (Table S2 ). In summary, RyR2-P1124L predisposes 8 mo-old mice to develop cardiac arrhythmia before the onset of hypertrophy at 1 yr of age. This suggests that the arrhythmia is a result of RyR2 dysfunction rather than cardiac structural remodeling. Furthermore, these data suggest that the cellular mechanism for the ventricular arrhythmias in P1124L mice is diastolic SCR.
Discussion
In 2006, Fujino et al. reported for the first time a RyR2 mutation in a family with HCM, T1107M (13). Two subsequent, separate studies showed that this mutation alters the structure of the SPRY2 domain (19) and produces a loss-of-function phenotype (14) . Medeiros-Domingo et al. later identified this mutation in patients with CPVT, the inherited arrhythmia already strongly associated with RyR2 dysfunction (16), weakening its exclusive association with HCM. T1107M
is not a conserved residue among species and two studies questioned its pathogenicity altogether because it appears with relatively high frequency in WES cohorts (seen in 118 of 277,072 alleles, frequency of 0.0004) (15, 32, 33) , higher than the prevalence of CPVT. In this report, we thoroughly characterized the novel RyR2-P1124L mutation, detected in a patient with obstructive HCM. P1124L also appears in publicly available exome databases, although with a ~20-fold lower frequency than T1107M and we propose its association with a disease with much higher prevalence than CPVT. Hence, to our knowledge this is the first comprehensive study of a RyR2 mutation strongly associated with HCM, a structural disorder of the heart. We provide multiple layers of evidence, from single molecule to whole animal, suggesting a potential association between P1124L and HCM. Additionally, our data show that P1124L underlies an arrhythmogenic phenotype, suggesting that some RyR2 mutations may lead to presentations that cross the boundaries from purely functional (CPVT) to structural (HCM) alterations.
First, we show that P1124L involves a highly conserved residue among RyR isoforms and species and is located within SPRY2, one of the peripheral domains of RyR2, where it produces structural disturbances in arrangement of a flexible linker at the SPRY2-SPRY3 interface. P1124L
is one of a handful of mutations that fall outside of the canonical CPVT1-associated mutation "hotspots" of RyR2 ( Figure 1A ), which contain ~93% of the disease-causing mutations. Our model of the SPRY2-SPRY3 interface suggests that P1124L promotes intradomain rearrangement and alters interdomain interactions that could affect allosteric coupling mechanisms in the channel.
The large size of RyR2 makes it difficult to model single amino acid mutations using the whole channel protein; hence, the long-range effects of P1124L are not known. Even then, it is conceivable that the peripheral domains of RyR2 allosterically regulate channel gating or its association with protein partners. This idea is supported by the model suggesting that phosphorylation of S2814, also located in a peripheral domain of RyR2, may turn the channel "leaky" in some forms of heart disease (34). Ultimately, the consequence of the structural alterations to the SPRY region produced by P1124L appears to be a cytosolic loss-of-function, as we determined using two complementary assays, [ which we measured in the SCR assay in HEK293 cells. This is a rather distinct phenotype that, to our knowledge, has only been identified in one other mutation of variable penetrance linked to CPVT1 (24, 35) . While our experiments were carried out using homozygous P1124L channels, in the heterozygous condition, as in the patient, any phenotype will be the aggregate result the absolute expression of each allele and the resulting heterogeneous population of channels containing none to four mutant subunits. We have previously addressed this issue for two other CPVT1-related RyR2 mutations (31, 36) .
Second, we show that mice expressing RyR2-P1124L channels develop cardiac hypertrophy at 1 yr of age. This phenotype, albeit mild, involves a significant increase in LV wall thickness, myocyte size and ANP expression in homozygous mice. Het hearts (resembling the genotype of the human patient), on the other hand, show only a tendency for hypertrophy. As there are significant differences between mouse and human cardiac physiology that can modify the effect of specific mutations, it is not entirely surprising that mice may show a milder phenotypic penetrance. For example, mutations that truncate MyBP-C are overtly hypertrophic in heterozygous humans (37) , but produce cardiomyopathy only in homozygous mice (38) (39) (40) .
Additionally, the penetrance and expressivity of a specific mutation may be affected by the genetic background of the mouse model, as has been previously recognized (41) . Indeed, we have observed phenotypic differences between P1124L in the C57Bl/6 genetic background used in this study and a strain with a mixed Sv129/C57Bl6 background (FJA, unpublished observations).
To our knowledge, this report is the first instance in which a clinically relevant RyR2 mutation produces cardiac hypertrophy of any degree in an animal model. In our search for the Figure S1 and Table S4 ) suggest there are no differences in the force of contraction, provided there are no changes in the sensitivity of the myofilaments to Ca 2+ . At this point we have no evidence of such alterations. The link between the unique biophysical properties uncovered for P1124L, the increase in CaM expression and the hypertrophic phenotype observed in P1124L remains to be elucidated. We surmise that subjecting P1124L mice to chronic stress through drug treatments or a surgical approach to induce heart failure may provide additional insight into the pathogenicity of the mutation. Together with the possible influence of the genetic background over the phenotype of the mouse model, as discussed previously, this notion will require further studies.
Finally, we observed cardiac arrhythmia, particularly BDVT, in 8 mo-old P1124L mice undergoing arrhythmia challenge. In HCM, ventricular arrhythmias often develop because of the extensive structural and electrophysiological remodeling (42) . Interestingly, P1124L mice show both structural and functional phenotypes independently (arrhythmia at 8 mo and hypertrophy at 1 yr, respectively). Unlike hypertrophy, it is not unexpected to link RyR2 mutations with cardiac arrhythmias since many have been documented to cause CPVT1. From the molecular phenotypes we uncovered for P1124L channels, cytosolic loss-of-function and luminal gain-offunction, the latter may be more prone to drive the arrhythmia process: spontaneous activation of RyR2-P1124L during diastole may produce larger Ca 2+ releases that can diffuse to neighboring RyR2 clusters and propagate as arrhythmogenic Ca 2+ waves. These events may activate NCX during diastole and produce triggered activity due to delayed afterdepolarizations. Indeed, we observed a high incidence of diastolic SCR in myocytes from P1124L hearts even under basal conditions; however, it was Iso treatment which uncovered an evident increase in the frequency of such events. These observations are consistent with the mechanisms broadly assigned to gainof-function RyR2 mutations (10) . In contrast, mutations that depress channel function favor a mechanism involving sustained bursts of Ca 2+ leak after the peak of a Ca 2+ transient, leading to early afterdepolarizations (36) . In both cases, however, a form of stress (e.g. arrhythmia challenge or Iso) seems necessary to create the substrate required to promote aberrant Ca 2+ release and arrhythmia.
As expected from the literature, WT mice did not show BDVT. However, both Het and Homo mice did show this type of arrhythmia, although the incidence was not statistically significant between Het and WT mice. In Het mice, permutation analysis predicts that most RyR2 channels should contain at least one P1124L subunit, and ~6% of the channels should contain four P1124L subunits (31, 36) . This distribution may be skewed if one allele is expressed more predominantly; nonetheless, in the cellular mechanism discussed above, homozygous channels are likely driving the arrhythmogenic phenotype.
Clinical Relevance
Following its discovery in a patient with HCM, P1124L was classified as a VUS based on ACMG guidelines (17) . Our characterization of P1124L in different model systems adds an important layer of evidence to classify P1124L as 'likely pathogenic (III)' in the context of HCM, with one strong (PS3) and two moderate (PP3, PP4) supporting criteria. The presence of both hypertrophy and increased susceptibility to arrhythmia in P1124L mice suggest that certain RyR2 variants could lead to both phenotypes, as discussed next. This is a tantalizing idea that requires further research, but the significant differences in mouse and human cardiac physiology and Ca
2+
handling could make the mouse a less-than-ideal model to address these questions.
Since the identification of the first mutation associated with HCM affecting myosin heavy chain 7 in 1990 (MYH7-R403Q) (43) , the number of genes and variants associated with HCM continues to grow. Even as HCM is overwhelmingly recognized as a monogenic disease caused primarily by mutations in sarcomeric genes, the fact that nearly half of the patients lack a genetic diagnosis cannot be overlooked. This large proportion of mutation-negative cases suggests HCM has unknown genetic causes if we continue to consider HCM predominantly a monogenic disease; alternatively, it suggests that HCM may also appear as a complex disorder in which genetic modifiers and factors such as age, gender, comorbidities and lifestyle intervene in the phenotypic outcome (44) . This idea is increasingly recognized, and the variable inheritance of non-sarcomeric HCM may favor a multifactorial model (42, 45 ).
As we propose to consider a novel association between RyR2 mutations and nonsarcomeric HCM, and due to the mild hypertrophic phenotype present only in homozygous mice, it is important to consider the possibilities outlined above. The role of RYR2 as a CPVT gene is robust, therefore the increased susceptibility of P1124L mice to arrhythmia is not surprising.
However, some mutations, such as P1124L, might in fact present not only as pro-arrhythmic variants but also as HCM modifiers. In this scenario, P1124L may generate a pro-hypertrophic substrate in association with other variables, fitting within a multifactorial HCM model. familial assessment was not possible in this study and we cannot test the possibility that the patient acquired a de novo mutation or shows genetic mosaicism.
In conclusion, although our data does not provide unequivocal evidence to classify RYR2
as an HCM-causing gene, it presents a compelling argument for the importance of studying and understanding the possible implication of rare genes in different forms of HCM. Ultimately, this is an important effort to elucidate the variable disease penetrance and determine the causes of genotype-negative HCM. (17) .
Methods
Identification of RyR2-P1124L in a Human Patient with Clinically Diagnosed HCM
Crystallization of SPRY2
Mouse RyR2 SPRY2 domain (residues 1080-1253) including the P1124L substitution was cloned, expressed and purified according to a similar strategy previously used for WT RyR2 SPRY2 domain (19) . Protein crystals were grown using hanging drop method at 20°C. P1124L (5 mg/mL) was crystallized in 0.1 M potassium thiocyanate, 25-35% PEG2000MME with seeding of WT crystals. Crystals were harvested and flash frozen in the original growth condition supplemented with 25-30% glycerol. Diffraction data were collected at the Advanced Photon Source (APS) beamline 23ID-D. Data were processed with HKL2000. The WT RyR2 SPRY2 structure (PDB ID 4P9I) was used as a search model for molecular replacement to solve the RyR2 SPRY2 P1124L mutant structure. The structure was refined using successive rounds of manual building in COOT (51) and automated refinement using Phenix (52) . The statistics for data collection and refinement is shown in Table S1 . Coordinate and structure factor for P1124L is available in the Protein Data Bank (www.rcsb.org) with accession code 5VSN.
Transient Expression of RyR2 in HEK293 Cells
HEK293 cells were grown in DMEM supplemented with 10% FBS, 100 U/mL penicillin and 100 μg/mL streptomycin on 100 mm tissue culture dishes. Cells were transfected with a plasmid containing the mouse Ryr2 cDNA using the Xtreme-DNA reagent (Roche Laboratories), following the instructions of the manufacturer. Cell lysates were prepared from transfected cells as previously described (36) . 48 h after transfection, cells were washed twice with PBS, then scraped from the plate and solubilized in 200 μL of lysis buffer, containing 25 mM Tris/50 mM HEPES (pH 7.4), 137 mM NaCl, 1% CHAPS, 0.5% soybean phosphatidylcholine, 2.5 mM DTT, and protease inhibitors (2 µM leupeptin, 100 µM phenylmethylsulphonyl fluoride, 500 µM benzamidine, 100 nM aprotinin). The cells were incubated on ice for 1 h and lysates were obtained by centrifuging at 16,000 × g at 4 °C for 10 min to remove insoluble material. Protein concentrations were determined using the Bradford method (Bio-Rad).
[
H]Ryanodine Binding Assays
Binding assays were carried out following a modified version of a protocol previously described (53 Images were captured at room temperature using a LSM800 confocal microscope (Carl Zeiss) with a Plan-Apochromat 20X/0.8 M27 objective at 405 nm excitation, and 400-500 nm (CFP) and 500-700 (YFP) emission. Time-lapse images were collected every 1.5 s with a scanning time of 1.29 s/frame. FRET was calculated as the YFP/CFP ratio. The maximum store capacity, fractional release, and activation and termination thresholds were calculated using the following equations, where FAct and FTerm are the FRET levels when spontaneous Ca 2+ oscillations activate and terminate, FMax is the maximum FRET level with tetracaine perfusion, and FMin is the residual FRET level after the ER is emptied with caffeine.
Generation of the RyR2-P1124L Targeted Mice
The RyR2-P1124L-KI targeting vector was constructed using a combination of traditional cloning techniques and "recombineering", a highly efficient phage-based Escherichia coli homologous recombination system (55, 56) . 
Mouse Phenotyping
Transthoracic echocardiography (Echo) was performed by the Echocardiography Service of the Frankel Cardiovascular Center Animal Phenotyping Core at the University of Michigan using a Vevo 2100 system with a 22-55 MHz transducer (MS550D; Visual Sonics), as described previously (59) . Mice were anesthetized with 1-2% isoflurane and maintained on a heated platform. Two-dimensionally guided M-mode images of the left ventricle were acquired at the tip of the papillary muscles. Left ventricle diameter, septum wall and posterior wall thickness were recorded to determine the fractional shortening, LV volume, ejection fraction, and heart rate. All parameters were measured over at least three consecutive cycles.
Surface electrocardiograms were recorded as described previously (31) . Mice were anesthetized with isoflurane (2-5%) and maintained on a heated pad. Needle electrodes were placed under the skin to record in Lead-I and Lead-II configurations, using a PowerLab system (ADInstruments). After 5-10 minutes of stable baseline recording, epinephrine (2 mg/kg) and caffeine (120 mg/kg) were applied i.p. Animals were monitored for 30 minutes after injection in search of arrhythmic events (typically ventricular bigeminy and ventricular tachycardia) defined as 3 or more ventricular ectopic beats, consecutive or alternated with normal beats. These events were further classified as non-sustained (lasting less than 5 seconds) or sustained (lasting 5 seconds or longer).
For histological staining, FFPE hearts were sectioned, stained and imaged by the Unit of Laboratory Animal Medicine In-Vivo Animal Core at the University of Michigan. An expert pathologist performed a detailed analysis of the slides and quantified the level of fibrosis.
The experimenter was blinded in all procedures performed at institutional cores. Age-and gender-matched WT littermates and C57Bl/6 mice were used as controls. All sets include males and females. Numbers and age of the mice are indicated in each figure.
Tissue Homogenization
Whole heart homogenates were prepared as previously described (60) . Briefly, frozen hearts were pulverized in liquid nitrogen, suspended in homogenization buffer (0.9% NaCl, TrisHCl 10 mM pH 6.8, 20 mM NaF, 2 µM leupeptin, 100 µM phenylmethylsulphonyl fluoride, 500 µM benzamidine, 100 nM aprotinin), homogenized using a Teflon pestle, and centrifuged at 1000 x g for 10 minutes at 4 °C. Supernatants were aliquoted and stored at -80 °C until used. Protein concentrations were determined using the Bradford method (Bio-Rad).
Western Blotting 50 µg of tissue homogenate were suspended in Laemmlii buffer and separated by SDS-PAGE in 4-20% TGX or AnyKD precast gels (Bio-Rad). Proteins were then transferred to PVDF membranes using the iblot2 transfer system (ThermoFisher) or overnight wet transfer. with the ImageLab software (Bio-Rad). Custom-made antibodies against the phosphorylated forms of RyR2 are described elsewhere (60) .
Single Channel Recordings
Cardiac SR-enriched microsomes for single channel recordings were prepared from mouse hearts using differential centrifugation, as previously described (36) . 10-15 pooled mouse hearts were homogenized as described above. Homogenates were centrifuged a second time at 8000 x g for 20 minutes at 4˚C. Supernatants were further centrifuged at 100,000 x g for 35 minutes at 4˚C. The pellets containing SR-enriched microsomes were resuspended in homogenization buffer supplemented with 0.3 M sucrose.
RyR2 channels from SR microsomes were incorporated into planar lipid bilayers to record single channel activity as previously reported (36) . The trans (1000 µl) and the cis (1000 µl) chambers (corresponding to the luminal and cytoplasmic side of the channel) contained 300 and Bessel filter set at 1.5 kHz, and digitized at a rate of 4 kHz using a Digidata 1200 AD/DA interface (Molecular Devices). Data acquisition and analysis was performed with Axon Instruments hardware and software (pClamp 10, Molecular Devices).
Gene Expression Analysis
Tissue was homogenized in TRIzol reagent (ThermoFisher) following the manufacturer's instructions. After addition of an appropriate amount of chloroform, mixing, incubation, and centrifugation, the RNA-containing aqueous phase was collected and treated with DNase I (Qiagen) for one hour. RNA was subsequently purified using the RNeasy mini kit (Qiagen), following the manufacturer's protocol. First strand cDNA synthesis was performed using the iScript Reverse Transcription Kit (Bio-Rad). To facilitate full length first strand cDNA synthesis, samples were incubated for 90 minutes at 50 ˚C prior to heat inactivation of the reverse transcriptase at 70 ˚C for 15 minutes. Expression levels of Nppa (Mm01255748_g1, ThermoFisher), Nppb (Mm01255770_g1, ThermoFisher), Myh7 (Mm00600555_m1, ThermoFisher), and Actb (4352933E, ThermoFisher) were assessed using TaqMan gene expression probes.
Isolation of Ventricular Myocytes
Ventricular myocytes were isolated as previously described (59, 61) . Briefly, mice were heparinized (0.5 U/g IP, Sagent Pharmaceuticals) and anesthetized with urethane (1mg/kg IP, Sigma-Aldrich). The heart was quickly excised, mounted on a Langendorff apparatus, and perfused with Perfusion Buffer (PB) containing (mM) 113 NaCl, 4. 
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